PN markedly enhanced the sensitivity of human lung cancer cells to oxaliplatin, an analog of cisplatin, by inhibiting NF-κB activation (Figure 2, Section 1) and inducing apoptosis [127]. This evidence concerns the gene NFKB1 and lung carcinoma.